Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916205 | 0.84 | ALDH1A1 (0.46) | ALOX15ALDH1A1LMNAL3MBTL1MAPT | |
| SCHEMBL1710999 | 0.81 | ALOX15 (0.53) | ALOX15ALDH1A1LMNAL3MBTL1MAPT | |
| SCHEMBL29951458 | 0.74 | ALOX15 (0.58) | ALOX15ALDH1A1LMNAMAPTPOLB | |
| SCHEMBL12346499 | 0.74 | LMNA (0.71) | ALDH1A1LMNAL3MBTL1MAPTPOLB | |
| SCHEMBL12346533 | 0.73 | ALDH1A1 (0.49) | ALOX15ALDH1A1LMNAL3MBTL1MAPT | |
| SCHEMBL1723082 | 0.73 | ALOX15 (0.55) | ALOX15ALDH1A1LMNAMAPTPOLB | |
| SCHEMBL7252037 | 0.71 | ALOX15 (0.46) | ALOX15ALDH1A1LMNAMAPTPOLB | |
| SCHEMBL7249984 | 0.70 | ALDH1A1 (0.50) | ALOX15ALDH1A1LMNAMAPTPOLB | |
| SCHEMBL15333406 | 0.70 | FBP1 (0.54) | ALOX15ALDH1A1LMNAL3MBTL1MAPT | |
| SCHEMBL7518403 | 0.70 | ALDH1A1 (0.55) | ALOX15ALDH1A1LMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372230-B1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3173415-B1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3372230-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | Agios Pharmaceuticals, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2704719-B1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS INC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9707230-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707230-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707230-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3173415-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-3173415-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9403792-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-08-02 | — | — | US | disclosed |
| US-8841305-B2 | Activators of the human pyruvate kinase M2 receptor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-29 | — | — | US | disclosed |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US Dept. of Health and Human Services (US) | 2011-08-11 | — | — | US | disclosed |
| EP-2344453-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042867-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042867-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148444-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK2, PCK2 | ALOX15 3519/4885ALDH1A1 1394/4885LMNA 1891/4885 |
| US-20110195958-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | ALOX15 4584/4885ALDH1A1 1687/4885LMNA 1711/4885 |
| US-20120245141-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | ALOX15 3998/4885ALDH1A1 1852/4885LMNA 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.